ASH 2024: Global Updates in the Management of Chronic Lymphocytic Leukemia - Episode 5
Clinical Insights and Real-World Evidence
Carsten Niemann, MD, PhD, Arnon Kater, MD, PhD, Othman Al-Sawaf, MD, John F. Seymour, MBBS, FRACP, PhD Panelists discuss, which patients are favored for the Venetoclax-Obinutuzumab treatment approach.
Video content above is prompted by the following:
- In which patients would you favor the Venetoclax-Obinutuzumab treatment approach?